NL-OMON50998
Completed
Not Applicable
A Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Doses of LY3526318 in Healthy Participants - A safety, PK and pilot FE study of LY3526318 in healthy participants
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Eli Lilly
- Enrollment
- 16
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Aged 18 to 65 years, inclusive.
- •2\. Healthy male participants, as determined through medical history and physical
- •examination.
- •a. A nonvasectomized, male participant must agree to use a condom or abstain
- •sexual intercourse from start of dosing until 105 days beyond the last dose of
- •intervention.
- •b. No restrictions are required for a vasectomized male provided his vasectomy
- •performed at least 4 months or prior to screening. A male who has been
- •vasectomized
- •\*4 months prior to screening must follow the same restrictions as a
Exclusion Criteria
- •1\. Have a history or presence of medical illness including, but not limited to,
- •cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric or
- •neurological
- •disease, convulsions, or any clinically significant laboratory abnormality
- •that, in the
- •judgment of the investigator, indicate a medical problem that would preclude
- •participation.
- •2\. Any abnormalities identified following a physical examination of the
- •participant that, in
- •the opinion of the investigator, would jeopardize the safety of the participant
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Safety, Tolerability and Pharmacokinetics of Tirzepatide in Pediatric Participants with Obesity.Weight managementMedDRA version: 20.0Level: HLTClassification code 10027428Term: Metabolic disorders NECSystem Organ Class: 100000004861Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]EUCTR2024-000081-22-Outside-EU/EEAEli Lilly and Company
Active, not recruiting
Phase 1
Safety, tolerability, and pharmacokinetics study of turoctocog alfa pegol injected under the skin in patients with haemophilia AEUCTR2016-002396-99-FRovo Nordisk A/S36
Active, not recruiting
Phase 1
Safety, tolerability, and pharmacokinetics study of turoctocog alfa pegol injected under the skin in patients with haemophilia AHaemophilia AMedDRA version: 19.0Level: LLTClassification code 10018938Term: Haemophilia A (Factor VIII)System Organ Class: 100000004850Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2016-002396-99-DEovo Nordisk A/S48
Active, not recruiting
Phase 1
Safety, tolerability, and pharmacokinetics study of turoctocog alfa pegol injected under the skin in patients with haemophilia AEUCTR2016-002396-99-BGovo Nordisk A/S36
Active, not recruiting
Phase 1
Safety, tolerability, and pharmacokinetics study of turoctocog alfa pegol injected under the skin in patients with haemophilia AEUCTR2016-002396-99-GBovo Nordisk A/S36